Overview

A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety of chronic use of abatacept in Japanese Subjects with Rheumatoid Arthritis (RA) having completed clinical studies IM101-071, IM101-034, and also Disease Modifying Anti-Rheumatic Drugs (DMARDs) failures with MTX intolerance.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept